𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reduction in the toxicity of aminopterin—monoclonal-antibody conjugates by leucovorin

✍ Scribed by A. J. Rowland; G. A. Pietersz

Book ID
105229559
Publisher
Springer-Verlag
Year
1994
Tongue
English
Weight
498 KB
Volume
39
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monoclonal antibody drug conjugates in t
Monoclonal antibody drug conjugates in the treatment of cancer
✍ Pamela A Trail; Albert B Bianchi 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugated to drugs with different mechanisms of action and different levels of potency. Monoclonal-antibody-directed drug delivery has the potential to both improve efficacy and reduce systemic toxicity. Several immuno

In vitro neutralization of T-2 toxin tox
In vitro neutralization of T-2 toxin toxicity by a monoclonal antibody
✍ Dr. Fiorenza Minervini; Agnes Gyongyosi-Horvath; Giacomo Lucivero; Angelo Viscon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB

A T-2 toxin specific monoclonal antibody, IgGl K, with a low level of ELISA cross-reactivity to Acetyl T-2, HT-2, and is0 T-2 toxins has been produced. The ability of this monoclonal antibocly to neutralize the cytotoxicity of T-2 toxin in PHA stimulated cultures of human lymphocytes was determined

In vivo efficacy of monoclonal antibody
In vivo efficacy of monoclonal antibody — drug conjugates of three different subisotypes which bind the human tumor — associated antigen defined by the KS1/4 monoclonal antibody
✍ James J. Starling; Ronald S. Maciak; N. Ann Hinson; Cynthia L. Nichols; Stephen 📂 Article 📅 1989 🏛 Springer-Verlag 🌐 English ⚖ 925 KB

A panel of three hybridomas has been isolated each of which secretes a single species of monoclonal antibody (MoAb) directed against the KS1/4 tumor-associated antigen originally described by Varki et al. (Cancer Res 44: 681, 1984). These MoAbs were designated L1-(IgG2b), L2-(IgG1), and L4-(IgG2a)KS